RDIF awaiting SEC recommendation for Sputnik approval in India

New Delhi | The Russian Direct Investment Fund said on Monday it is “awaiting imminently” the recommendation by the Subject Expert Committee (SEC) of India’s Central Drugs Standard Control Organisation (CDSCO) to approve the use of the Russian Sputnik V vaccine against coronavirus in the country.

The comment by RDIF came amid reports that India has approved the Sputnik vaccine.

“RDIF confirms it is awaiting imminently the recommendation by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) of India to approve the use of the Russian Sputnik V vaccine against coronavirus in India,” RDIF told IANS.

The RDIF, Russia’s sovereign wealth fund, recently announced the results of a YouGov survey with 9,417 respondents from 9 countries on their vaccine preferences and country of preference in terms of vaccine production.

According to the survey, 54 per cent of respondents who selected a country they trust to produce a vaccine, considered Russia the most trusted vaccine producer alongside the US and leaving the UK behind, when asked to choose the 3 countries they trusted the most to produce a vaccine.

Sputnik V, the world’s first registered vaccine against coronavirus, is the most recognizable one – over 7 in 10 (74 per cent) of those surveyed have heard of the Russian vaccine. Sputnik V is also among Top-2 most preferred vaccines, just after the one produced by Pfizer/BioNTech.

The survey was conducted between February 18 and March 3 by YouGov, the leading UK-based company in market research and data analytics in Asia, Latin America, the Middle East, North Africa and Europe. Residents of India, Brazil, Mexico, the Philippines, Vietnam, Argentina, Algeria, the UAE and Serbia participated in the poll. More than 2 billion people, or over 25 per cent of the world’s population, live in these countries.

IANS

The English Post is on Telegram, click to join for regular news updates